Quote:
Originally Posted by 'Hamas' Jenkins
Beta-blockers, potassium-sparing diuretics, and ACE-Inhibitors all have a demonstrable mortality benefit in patients with heart failure whose ejection fraction is <40%. That doesn't mean that they reduce the risk of death to 0, and it doesn't mean that their use represents a gray area. There is a clear benefit: the people who take them are less likely to die than matched controls that don't.
Notice that mitigation strategies are trying to get the R0 as low as possible. They aren't designed with a goal to get it to 0.
You have a fundamental misunderstanding of what the goal is.
|
No, I don't have a misunderstanding at all. I am just posting data that you don't agree with, which is fine.